

L Number	Hits	Search Text	DB	Time stamp
1	396	(546/122).CCLS.	USPAT	2003/12/22 16:58
3	790	(514/300).CCLS.	USPAT	2003/12/22 16:58

L Number	Hits	Search Text	DB	Time stamp
1	396	(546/122).CCLS.	USPAT	2003/12/22 16:58
2	127	(546/138).CCLS.	USPAT	2003/12/22 16:58
3	790	(514/300).CCLS.	USPAT	2003/12/22 16:58
4	102	(514/306).CCLS.	USPAT	2003/12/22 16:58

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	DEC 08	INPADOC: Legal Status data reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	16	NOV 24	MSDS-CCOHS file reloaded
NEWS	17	DEC 08	CABA reloaded with left truncation
NEWS	18	DEC 08	IMS file names changed
NEWS	19	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	20	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	21	DEC 17	DGENE: Two new display fields added
NEWS	22	DEC 18	BIOTECHNO no longer updated
NEWS	23	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	24	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	25	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	26	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10/031,844

V. Balasubramanian

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:38:00 ON 22 DEC 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:38:08 ON 22 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2003 HIGHEST RN 629597-20-2

DICTIONARY FILE UPDATES: 21 DEC 2003 HIGHEST RN 629597-20-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10031844.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1


=> d l1

L1 HAS NO ANSWERS

L1 STR

10/031,844

V. Balasubramanian



G1 C,N

G2 C,O,S,N

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:38:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9028 TO ITERATE

11.1% PROCESSED 1000 ITERATIONS

5 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 174868 TO 186252

PROJECTED ANSWERS: 499 TO 1305

L3 5 SEA SSS SAM L1

=> d scan

V. Balasubramanian


L3 5 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN Acetamide, 2-[[1-[(2R)-2-hydroxy-2-(6-methoxy-4-quinolinyl)ethyl]-4-


MF RV SR T S A R R R T

CM 1

Absolute stereochemistry.



CM 2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

V. Balasubramanian

L3 5 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
MF RT RW V T

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

V. Balasubramanian


L3 5 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-[3-[[1-[(2R)-2-hydroxy-2-(6-methoxy-4-quinolinyl)ethyl]-4-piperidinyl]amino]propyl]-, ethanedioate (1:2)
(salt) (9CI)


MF RT SP U T A R R R T

CM 1

Absolute stereochemistry.



CM 2




V. Balasubramanian

L3 5 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN 1-Piperidinecarboxamide, N-(5,8-difluoro-6-methoxy-4-quinolinyl)-4-[(8-hydroxy-2-quinoxaliny)methyl]amino]- (9CI)

MF RU RT R V S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

V. Balasubramanian

L3 5 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2-Propenamide, N-[1-[(2R)-2-hydroxy-2-(6-methoxy-4-quinolinyl)ethyl]-4-piperidinyl]-3-(3-thienyl)-, (2E)- (9CI)
MF RT RW S S #
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

V. Balasubramanian

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.40

0.61

STN INTERNATIONAL LOGOFF AT 15:38:59 ON 22 DEC 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 DEC 08 INPADOC: Legal Status data reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded
NEWS 17 DEC 08 CABA reloaded with left truncation
NEWS 18 DEC 08 IMS file names changed
NEWS 19 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 20 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 21 DEC 17 DGENE: Two new display fields added
NEWS 22 DEC 18 BIOTECHNO no longer updated
NEWS 23 DEC 19 CROPU no longer updated; subscriber discount no longer
available
NEWS 24 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS
databases
NEWS 25 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 26 DEC 22 ABI-INFORM now available on STN

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability

10/031,844

V. Balasubramanian

NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:41:57 ON 22 DEC 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:42:06 ON 22 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2003 HIGHEST RN 629597-20-2

DICTIONARY FILE UPDATES: 21 DEC 2003 HIGHEST RN 629597-20-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10031844q.str

L1 STRUCTURE UPLOADED

=> que L1

10/031,844

V. Balasubramanian

L2 QUE L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10031844.str

L3 STRUCTURE UPLOADED


=> que L3

L4 QUE L3

=> d l3

L3 HAS NO ANSWERS

L3 STR



G1 C,N

G2 C,O,S,N

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3 not l1 ss sam

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> s l3 not l1 sss sam

SAMPLE SEARCH INITIATED 15:43:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9028 TO ITERATE

11.1% PROCESSED 1000 ITERATIONS

1 ANSWERS

10/031,844

V. Balasubramanian

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 174868 TO 186252
PROJECTED ANSWERS: 1 TO 360


L5 1 SEA SSS SAM L3 NOT L1

=> d scan

V. Balasubramanian

L5 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
MF RT RW V T

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

V. Balasubramanian

=> s l3 not l1 sss ful

FULL SEARCH INITIATED 15:43:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 180571 TO ITERATE

100.0% PROCESSED 180571 ITERATIONS

105 ANSWERS

SEARCH TIME: 00.00.03

L6 105 SEA SSS FUL L3 NOT L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.95

149.16

FILE 'CAPLUS' ENTERED AT 15:43:53 ON 22 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2003 VOL 139 ISS 26

FILE LAST UPDATED: 21 Dec 2003 (20031221/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6

L7 6 L6

=> d l7 1-6 bib hitstr

V. Balasubramanian

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:610459 CAPLUS
DN 139:164795
TI Preparation of aminopiperidine compounds as antibacterial agents
IN Miller, William Henry; Pearson, Neil David; Pendrak, Israil; Seefeld, Mark Andrew
PA Glaxo Group Limited, UK; Daines, Robert A
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064431	A2	20030807	WO 2003-EP824	20030127
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2002-2025 A 20020129
GB 2002-29819 A 20021220

OS MARPAT 139:164795


IT 577771-04-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminopiperidine compds. as antibacterial agents)

RN 577771-04-1 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[3-fluoro-4-[[[1,2,3]thiadiazolo[5,4-b]pyridin-6-ylmethyl)amino]-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 577771-13-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

10/031,844


V. Balasubramanian

(prepn. of aminopiperidine compds. as antibacterial agents)

RN 577771-13-2 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[(4-amino-3-fluoro-1-piperidiny)methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:610449 CAPLUS

DN 139:164798

TI Preparation of aminopiperidine derivatives for treatment of bacterial infections

IN Miller, William Henry; Pearson, Neil David; Pendrak, Israil; Seefeld, Mark Andrew

PA Glaxo Group Limited, UK; Daines, Robert A

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064421	A1	20030807	WO 2003-EP823	20030127
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2002-2026	A	20020129		
	GB 2002-29824	A	20021220		
OS	MARPAT 139:164798				
IT	577691-48-6P , 6-[[[(2S,4S)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one 577691-49-7P , 6-[[[(3R,4S)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-3-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one 577691-50-0P , 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-4-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one 577692-02-5P , 6-[[[(3S,4R)-3-Fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one 577692-04-7P , 6-[[[(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one 577692-06-9P , 6-[[[(3S,4R)-3-Fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one 577692-07-0P , 6-[[[(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one 577692-08-1P , 7-Chloro-6-[[[(3S,4R)-3-fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one 577692-09-2P , 7-Chloro-6-[[[(3R,4S)-3-fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one 577692-17-2P 577692-18-3P 577692-37-6P , 6-[[[(3S,4R)-3-Fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one 577692-38-7P , 6-[[[(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one 577692-40-1P ,				

6-[[[(2S,4S)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one **577692-41-2P**, 6-[[[(2S,4R)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one **577692-55-8P**

, 6-[[[(2R,4S)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one **577692-56-9P**, 6-[[[(2R,4R)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminopiperidine derivs. for treatment of bacterial infections)

RN 577691-48-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(2S,4S)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577691-49-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(3R,4S)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-3-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




V. Balasubramanian

RN 577691-50-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-(trifluoromethyl)-4-piperidiny]amino]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-02-5 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[(3S,4R)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidiny]amino]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 577692-04-7 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidiny]amino]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 577692-06-9 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[(3S,4R)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-07-0 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-08-1 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 7-chloro-6-[[[(3S,4R)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 577692-09-2 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 7-chloro-6-[[[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 577692-17-2 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[(3R,4S)-3-fluoro-1-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 577692-18-3 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[(3S,4R)-3-fluoro-1-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 577692-37-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(3S,4R)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 577692-38-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 577692-40-1 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[(2S,4S)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-41-2 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[(2S,4R)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-55-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(2R,4S)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-56-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(2R,4R)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 577692-03-6P, (1R)-2-[(3S,4R)-4-Amino-3-fluoropiperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol 577692-05-8P, (1R)-2-[(3R,4S)-4-Amino-3-fluoropiperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol 577692-19-4P, rel-(3R,4S)-3-Fluoro-1-[2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-ylamine 577692-51-4P 577692-52-5P 577692-53-6P 577692-54-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of aminopiperidine derivs. for treatment of bacterial infections)

RN 577692-03-6 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[(3S,4R)-4-amino-3-fluoro-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-05-8 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[(3R,4S)-4-amino-3-fluoro-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 577692-19-4 CAPLUS

CN 4-Piperidinamine, 3-fluoro-1-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

V. Balasubramanian


Relative stereochemistry.



RN 577692-51-4 CAPLUS

CN Carbamic acid, [(2S,4S)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-52-5 CAPLUS

CN Carbamic acid, [(2S,4R)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/031,844

V. Balasubramanian

RN 577692-53-6 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[(2S,4S)-4-amino-2-(trifluoromethyl)-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 577692-54-7 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[(2S,4R)-4-amino-2-(trifluoromethyl)-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:555350 CAPLUS

DN 137:125092

TI Preparation of 4-piperidinyquinolines and nitrogenated analogs as antibacterial agents

IN Davies, David Thomas; Jones, Graham Elgin; Markwell, Roger Edward; Miller, William; Pearson, Neil David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056882	A1	20020725	WO 2002-EP587	20020122
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1359908	A1	20031112	EP 2002-702296	20020122
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	GB 2001-1577	A	20010122		
	WO 2002-EP587	W	20020122		
OS	MARPAT 137:125092				
IT	443955-20-2P , (R)-2-[4-[[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol 443955-39-3P , 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]oxazin-3-one 443955-57-5P , 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one 443955-59-7P , 4-Oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-7-sulfonic acid [1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amide 443956-65-8P , 7-Bromo-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amide 443956-67-0P , 3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amide RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antibacterial agent; prepn. of piperidinyquinolines and nitrogenated analogs as antibacterial agents)				
RN	443955-20-2	CAPLUS			
CN	1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]-1-piperidiny]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


V. Balasubramanian



RN 443955-39-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443955-57-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 443955-59-7 CAPLUS

CN 1,5-Benzothiazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443956-65-8 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazine-6-carboxamide, 7-bromo-3,4-dihydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-3-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443956-67-0 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazine-6-carboxamide, 3,4-dihydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-3-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **443955-21-3P**, (R)-2-[4-[[1-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol dioxalate **443955-33-7P** **443955-40-6P**, 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]oxazin-3-one dioxalate **443955-58-6P**, 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one dioxalate **443955-60-0P** **443955-80-4P**, 7-Fluoro-6-[[[1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one **443955-86-0P**, (R)-2-[4-[[1-[(7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol **443955-88-2P**, (R)-2-[4-[[1-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol **443955-91-7P**, (R)-1-(6-Methoxy[1,5]naphthyridin-4-yl)-2-[4-[[1-[(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)methyl]amino]piperidin-1-

yl]ethanol **443956-02-3P**, 7-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-1H-pyrido[2,3-b][1,4]thiazin-2-one **443956-07-8P**, 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one dihydrochloride **443956-12-5P**, 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one hydrochloride **443956-17-0P**, (R)-2-[4-[[[3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol hydrochloride **443956-20-5P**, 7-Bromo-6-[[[1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one **443956-26-1P**, 7-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-1H-pyrido[3,4-b][1,4]thiazin-2-one **443956-43-2P**, (R)-2-[4-[[[3,4-Dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol dihydrochloride **443956-54-5P** **443956-59-0P** **443956-64-7P**, 7-Bromo-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amide dihydrochloride **443956-66-9P**, 3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [1-[(R)-2-hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amide dihydrochloride **443956-81-8P** **443956-82-9P**, 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one **443956-83-0P**, 6-[[[1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one **443956-84-1P**, (R)-2-[4-[[[3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol **443956-88-5P**, (R)-2-[4-[[[3,4-Dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl]amino]piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol **443957-04-8P** **443957-05-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; prepn. of piperidinyquinolines and nitrogenated analogs as antibacterial agents)

RN 443955-21-3 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[[2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 443955-20-2

CMF C25 H30 N4 O4

Absolute stereochemistry.


V. Balasubramanian



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 443955-33-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)methyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 443955-32-6

CMF C24 H26 N6 O3 S




CM 2

CRN 144-62-7

10/031,844

V. Balasubramanian

CMF C2 H2 O4



RN 443955-40-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 443955-39-3

CMF C25 H29 N5 O4


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 443955-58-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 443955-57-5

CMF C25 H29 N5 O3 S

10/031,844

V. Balasubramanian


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 443955-60-0 CAPLUS


CN 1,5-Benzothiazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-4-oxo-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 443955-59-7

CMF C25 H29 N5 O5 S2

Absolute stereochemistry.




CM 2

V. Balasubramanian

CRN 144-62-7


CMF C2 H2 O4



RN 443955-80-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 7-fluoro-6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidiny]amino]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 443955-86-0 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[(7-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]-1-piperidiny]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443955-88-2 CAPLUS

10/031,844

V. Balasubramanian

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-yl)methyl]amino]-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443955-91-7 CAPLUS

CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)methyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443956-02-3 CAPLUS

CN 1H-Pyrido[2,3-b][1,4]thiazin-2(3H)-one, 7-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 443956-07-8 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 443956-12-5 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



● HCl

RN 443956-17-0 CAPLUS
CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)methyl]amino]-1-piperidinyl)methyl]-6-methoxy-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 443956-20-5 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 7-bromo-6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/031,844


V. Balasubramanian



RN 443956-26-1 CAPLUS

CN 1H-Pyrido[3,4-b][1,4]thiazin-2(3H)-one, 7-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 443956-43-2 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[[(3,4-dihydro-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)methyl]amino]-1-piperidinyl]methyl]-6-methoxy-, dihydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian




● 2 HCl

RN 443956-54-5 CAPLUS

CN 1,8-Naphthyridin-2(1H)-one, 3,4-dihydro-6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidiny]amino]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 443956-59-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)


CM 1

CRN 443956-58-9

CMF C24 H26 N6 O4

10/031,844


V. Balasubramanian



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 443956-64-7 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazine-6-carboxamide, 7-bromo-3,4-dihydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-3-oxo-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 443956-66-9 CAPLUS


CN 2H-Pyrido[3,2-b]-1,4-thiazine-6-carboxamide, 3,4-dihydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-3-oxo-,

10/031,844

V. Balasubramanian

dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 443956-81-8 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, 7-chloro-3,4-dihydro-N-[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443956-82-9 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 443956-83-0 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidiny]amino]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 443956-84-1 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[[3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)methyl]amino]-1-piperidiny]methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 443956-88-5 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[(3,4-dihydro-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)methyl]amino]-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443957-04-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)methyl]amino]-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-, 2-propenyl ester, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 443957-03-7

CMF C29 H33 N5 O5 S

Absolute stereochemistry.

10/031,844


V. Balasubramanian



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 443957-05-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)methyl]amino]-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

10/031,844

IT **394223-51-9P**, 4-(tert-Butyloxycarbonylamino)-1-[[(6-methoxy[1,5]naphthyridin-4-yl)amino]carbonyl]piperidine
394223-52-0P, 4-Amino-1-[[(6-methoxy[1,5]naphthyridin-4-yl)amino]carbonyl]piperidine **443955-32-6P**, 4-[[(3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)methyl]amino]piperidine-1-carboxylic acid (6-methoxy[1,5]naphthyridin-4-yl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of piperidinylquinolines and nitrogenated analogs as antibacterial agents)
RN 394223-51-9 CAPLUS
CN Carbamic acid, [1-[[(6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 394223-52-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-amino-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 443955-32-6 CAPLUS


V. Balasubramanian

CN 1-Piperidinecarboxamide, 4-[[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)methyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



IT **394223-10-0**, (R)-2-(4-Aminopiperidin-1-yl)-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of piperidinylquinolines and nitrogenated analogs as antibacterial agents)
RN 394223-10-0 CAPLUS
CN 1,5-Naphthyridine-4-methanol, .alpha.-[(4-amino-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:240761 CAPLUS

DN 136:279352

TI Prepn. and biol. activity of aminopiperidine-contg. quinolines as antibacterial agents especially for use in humans

IN Davies, David Thomas; Markwell, Roger Edward; Pearson, Neil David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 90 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024684	A1	20020328	WO 2001-EP10976	20010919
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002018192	A5	20020402	AU 2002-18192	20010919
	EP 1320529	A1	20030625	EP 2001-985253	20010919
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	GB 2000-23211	A	20000921		
	GB 2001-1628	A	20010122		
	WO 2001-EP10976	W	20010919		
OS	MARPAT 136:279352				
IT	405935-34-4P 405935-35-5P 405935-36-6P 405935-37-7P 405935-66-2P 405935-67-3P 405936-11-0P 405936-12-1P 405936-14-3P 405936-15-4P 405936-22-3P 405936-23-4P 405937-03-3P 405937-08-8P 405937-10-2P 405937-12-4P 405937-14-6P 405937-16-8P 405937-36-2P 405937-41-9P 405937-43-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. and antibacterial activity of aminopiperidine-contg. quinoline derivs.)				
RN	405935-34-4 CAPLUS				
CN	1-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[[2-oxo-2-(phenylamino)ethyl]amino]- (9CI) (CA INDEX NAME)				

V. Balasubramanian




RN 405935-35-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[[2-oxo-2-(phenylamino)ethyl]amino]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 405935-34-4

CMF C23 H26 N6 O3




CM 2

CRN 144-62-7

CMF C2 H2 O4


V. Balasubramanian



RN 405935-36-6 CAPLUS

CN Acetamide, 2-[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 405935-37-7 CAPLUS


CN Acetamide, 2-[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]-N-phenyl-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 405935-36-6

CMF C24 H29 N5 O3


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 405935-66-2 CAPLUS

CN 1-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[(2-

10/031,844

V. Balasubramanian

phenoxyethyl)amino]- (9CI) (CA INDEX NAME)




RN 405935-67-3 CAPLUS

CN 1-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[(2-phenoxyethyl)amino]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 405935-66-2


CMF C23 H27 N5 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




10/031,844

V. Balasubramanian

RN 405936-11-0 CAPLUS

CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[2-(2-pyridinyloxy)ethyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 405936-12-1 CAPLUS


CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[2-(2-pyridinyloxy)ethyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 405936-11-0

CMF C23 H29 N5 O3


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 405936-14-3 CAPLUS


CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[2-(2-pyridinyl)-2-propenyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/031,844

V. Balasubramanian

Double bond geometry as shown.



RN 405936-15-4 CAPLUS


CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[(2E)-3-(2-pyridinyl)-2-propenyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 405936-14-3

CMF C24 H29 N5 O2


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 405936-22-3 CAPLUS

CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[(2E)-3-(2-thiazolyl)-2-propenyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

V. Balasubramanian




RN 405936-23-4 CAPLUS
CN 1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[[(2E)-3-(2-thiazolyl)-2-propenyl]amino]-1-piperidinyl]methyl]-, (.alpha.R)-, dimethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 405936-22-3
CMF C22 H27 N5 O2 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 405937-03-3 CAPLUS
CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[2-(3,5-difluorophenoxy)ethyl]amino]-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 405937-02-2
CMF C24 H28 F2 N4 O3

V. Balasubramanian


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4





RN 405937-08-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[2-(3,5-difluorophenoxy)ethyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 405937-07-7

CMF C23 H25 F2 N5 O3



CM 2



CRN 144-62-7
CMF C2 H2 O4



RN 405937-10-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[[2-(2-pyridinyloxy)ethyl]amino]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 405937-09-9
CMF C22 H26 N6 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 405937-12-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-4-[[[(2E)-3-(2-pyridinyl)-2-propenyl]amino]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 405937-11-3

V. Balasubramanian

CMF C23 H26 N6 O2


Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4





RN 405937-14-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]ethyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 405937-13-5

CMF C23 H26 F2 N6 O2



CM 2



CRN 144-62-7
CMF C2 H2 O4



RN 405937-16-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]ethyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 405937-15-7
CMF C23 H27 F N6 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 405937-36-2 CAPLUS
CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[2-[(3-fluorophenyl)amino]ethyl]amino]-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

V. Balasubramanian


CRN 405937-35-1
CMF C24 H30 F N5 O2

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 405937-41-9 CAPLUS
CN Acetamide, 2-[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]-N-2-pyridinyl-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 405937-40-8
CMF C23 H28 N6 O3


Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

V. Balasubramanian



RN 405937-43-1 CAPLUS


CN Acetamide, N-(3,5-difluorophenyl)-2-[[1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]amino]-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 405937-42-0

CMF C24 H27 F2 N5 O3


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



IT 394223-10-0P 394223-51-9P 394223-52-0P

405937-77-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and antibacterial activity of aminopiperidine-contg. quinoline derivs.)

RN 394223-10-0 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[(4-amino-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

V. Balasubramanian




RN 394223-51-9 CAPLUS

CN Carbamic acid, [1-[[[6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-4-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 394223-52-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-amino-N-(6-methoxy-1,5-naphthyridin-4-yl)-(9CI) (CA INDEX NAME)




RN 405937-77-1 CAPLUS

10/031,844

V. Balasubramanian

CN Carbamic acid, [1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:90042 CAPLUS

DN 136:151082

TI Preparation of aminopiperidine quinolines and their azaisosteric analogs having antibacterial activity

IN Davies, David Thomas; Jones, Graham Elgin; Lightfoot, Andrew P.; Markwell, Roger Edward; Pearson, Neil David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002008224	A1	20020131	WO 2001-EP8604	20010725
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1305308	A1	20030502	EP 2001-969509	20010725
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012750	A	20030909	BR 2001-12750	20010725
	NO 2003000345	A	20030310	NO 2003-345	20030123
PRAI	GB 2000-18351	A	20000726		
	GB 2001-1629	A	20010122		
	WO 2001-EP8604	W	20010725		
OS	MARPAT 136:151082				
IT	394223-11-1P 394223-20-2P 394223-49-5P 394223-53-1P 394223-54-2P 394223-85-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of aminopiperidine quinolines and their azaisosteric analogs having antibacterial activity)				
RN	394223-11-1 CAPLUS				
CN	1,5-Naphthyridine-4-methanol, 6-methoxy-.alpha.-[[4-[(2-quinoxalinylmethyl)amino]-1-piperidinyl)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


V. Balasubramanian



RN 394223-20-2 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[[8-hydroxy-2-quinolinyl)methyl]amino]-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394223-49-5 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[[4,6-difluoro-1H-benzimidazol-2-yl)methyl]amino]-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian




RN 394223-53-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[[4,7-difluoro-1H-indol-2-yl)methyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 394223-54-2 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[[4,6-difluoro-1H-benzimidazol-2-yl)methyl]amino]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)

10/031,844


V. Balasubramanian

NAME)

PAGE 1-A




PAGE 2-A



RN 394223-85-9 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[[4-[[[(4,6-difluoro-2-benzothiazolyl)methyl]amino]-1-piperidinyl]methyl]-6-methoxy-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/031,844

V. Balasubramanian


IT 394223-10-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of aminopiperidine quinolines and their azaisosteric analogs
having antibacterial activity)

RN 394223-10-0 CAPLUS

CN 1,5-Naphthyridine-4-methanol, .alpha.-[(4-amino-1-piperidinyl)methyl]-6-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 394223-51-9P 394223-52-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aminopiperidine quinolines and their azaisosteric analogs
having antibacterial activity)

RN 394223-51-9 CAPLUS


CN Carbamic acid, [1-[[[6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 394223-52-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-amino-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031,844

V. Balasubramanian

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:78380 CAPLUS

DN 134:131437

TI Preparation of 1-quinolyl-2-aminopiperidinoethanols and analogs as bactericides

IN Davies, David Thomas; Lightfoot, Andrew; Markwell, Roger Edward; Pearson, Neil David

PA SmithKline Beecham P.L.C., UK

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007432	A2	20010201	WO 2000-EP6938	20000717
	WO 2001007432	A3	20010525		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1214314	A2	20020619	EP 2000-945938	20000717
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003505455	T2	20030212	JP 2001-512516	20000717
PRAI	GB 1999-17408	A	19990723		
	WO 2000-EP6938	W	20000717		
OS	MARPAT 134:131437				
IT	321997-67-5P 321997-79-9P 321997-80-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of 1-quinolyl-2-aminopiperidinoethanols and analogs as bactericides)				
RN	321997-67-5 CAPLUS				
CN	1-Piperidinecarboxamide, 4-(heptylamino)-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)				

V. Balasubramanian



RN 321997-79-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-(heptylamino)-1-[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl-, methyl ester (9CI) (CA INDEX NAME)



RN 321997-80-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(heptylamino)-4-(hydroxymethyl)-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



V. Balasubramanian

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

19.19

168.35

STN INTERNATIONAL LOGOFF AT 15:44:25 ON 22 DEC 2003